InCode BioPharmaceutics raises $2M to target autoimmunity
InCode BioPharmaceutics, a Lahaina, Hawaii, biotech targeting autoimmune and inflammatory disease, raised $2 million in a second funding round, VentureWire reports (subscription required). The funding was provided by Avalon Ventures.
InCode is developing what VentureWire vaguely describes as “therapeutic uses for certain amino-acid sequences in non-human proteins,” which sounds like they’ve bioharvested some peptides from other organisms that seem to have interesting properties. The company said the funding will carry its lead compound, which it calls rC3Decomplase, through preclinical lab and animal testing over the next 18 months.
Next Story: Aegerion Pharma yanks $81M IPO
Previous Story: Sigvion Capital aims for $100M healthcare-startup fund
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.